Loading company
Pacific Biosciences of California, Inc.
PACB · Nasdaq · ·
$1.96-0.8%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 5, 2026
Past performance
- 1W
- -13.3%
- 1M
- -0.3%
Pacific Biosciences of California, Inc. against medical devices
Pacific Biosciences of California, Inc. is the 51st largest of 133 graded companies. Showing 5 of them, including PACB itself. 10 more are in this industry but have no grade yet, so they are left out rather than shown blank.
| Company | Grade | Market value | Revenue | Profit margin | Free cash flow | Price to earnings |
|---|---|---|---|---|---|---|
| ENvue Medical, Inc.FEED | F- | — | $1.9M | -1,093.6% | -$11.7M | — |
| Abbott LaboratoriesABT | B | $188B | $48.2B | 9.7% | $6.8B | 40.35 |
| Medtronic plcMDT | A+ | $131.6B | $37.5B | 13.9% | $6.1B | 25.27 |
| Stryker Corp.SYK | A+ | $117.9B | $26.3B | 13.8% | $4.6B | 32.98 |
| Pacific Biosciences of California, Inc.PACB | F- | $611.8M | $161.4M | -81.3% | -$143.4M | — |
128 more medical devices companies
Graded on the same five checks, from their own SEC filings.
How it compares with its industry
Three ratings, each a percentile against the 141 companies we cover in Medical Devices. Deliberately kept apart rather than blended into one score — cheap, rising and well-run are three different facts, and a single number would hide which one is which.
Momentum
77of 100 in its industry
Above most of its industry
12 months to a month ago26.5%
6 months to a month ago41.4%
The most recent month is left out on purpose: returns tend to persist over 7–12 months and the newest one tends to reverse. This describes what the price has done, and says nothing about what it will do.
Value
27of 100 in its industry
Below most of its industry
Profit for the price-21.45%
Cash for the price-23.44%
Sales for the price26.38%
Assets for the price0.87%
Operating profit for the whole business—
Yields, so higher means cheaper — a loss-making company ranks last instead of dropping out. Cheap is not the same as good: a high yield is often a price that fell for a reason. Blended from 4 of 5 measures.
Capital allocation
0/4Poor
2 checks not reported
Return on capital-61.8%
Shareholder yield0.00%
Share count, 3 years39.4%
Net debt / EBITDA—
Insiders, 12 months-$1.2M
What management does with the money — scored on whatever the filings answer, never as a share of the total.
The six capital-allocation checks
- Return on the money invested-61.8% on invested capital
- Debt against earningsNo comparable earnings to measure debt against
- Cash returned to shareholdersKeeps essentially all of it
- Share count over three yearsShare count 39.4% higher over three years
- Payouts covered by cash flowPays out more than it generates
- Open-market insider buyingNet selling of $1.2M — not counted against the score
A description of where this company sits among its competitors, not a recommendation. Ratings updated Nov 14, 2026.
A blank price-to-earnings means a loss, not a missing figure — the ratio has no meaning when there are no earnings to divide by, and printing a negative one would make the least profitable company look the cheapest.
Grades are trailing twelve months from each company’s own SEC filings, so they move only when a company files. Every column is computed by the same code that graded Pacific Biosciences of California, Inc. on the overview — nothing here comes from a data vendor’s own ratios.
Industry membership is not a judgement about how similar two businesses are. It groups companies by what they are classified as, which is a starting point for comparison rather than a claim that they compete.